Periphere arterielle Verschlusskrankheit der unteren Extremitäten

Auch wenn die 2017 aktualisierten ESC/ESVS-Leitlinien bei komplexen Verschlüssen den Wert der Bypasschirurgie wieder in den Vordergrund gestellt haben, hat sich die interventionelle Behandlung der peripheren arteriellen Verschlusskrankheit der unteren Extremitäten als primär revaskularisierende Maßnahme in den meisten Gefäßzentren etabliert. Dieser Beitrag zeigt, welche Therapieverfahren abhängig von Zielgefäßregion die besten Behandlungsergebnisse erzielen.

Schlüsselwörter

periphere arterielle Verschlusskrankheit - Stent-Angioplastie - A. femoralis superficialis - kritische Extremitätenischämie

• Literatur

• 1 Fowkes FG, Rudan D, Rudan I. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329-1340
• 2 Norgren L, Hiatt WR, Dormandy JA. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl. S) S5-S67
• 3 Mustapha JA, Katzen BT, Neville RF. et al. Determinants of Long-Term Outcomes and Costs in the Management of Critical Limb Ischemia: A Population-Based Cohort Study. J Am Heart Assoc 2018; 7: e009724
• 4 Aboyans V, Ricco JB, Bartelink MEL. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816
• 5 Krankenberg H, Zeller T, Ingwersen M. et al. Self-Expanding Versus Balloon-Expandable Stents for iliac Artery Occlusive Disease: The Randomized ICE Trial. JACC Cardiovasc Interv 2017; 10: 1694-1704
• 6 Mwipatayi BP, Sharma S, Daneshmand A. et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg 2016; 64: 83-94.e1
• 7 Gouëffic Y, Della Schiava N, Thaveau F. et al. Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv 2017; 10: 1344-1354
• 8 Garcia L, Jaff MR, Metzger C. et al. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv 2015; 8 (05) pii : e000937 doi:10.1161/CIRCINTERVENTIONS.113.000937
• 9 Reijnen MMPJ, van Walraven LA, Fritschy WM. et al. 1-Year Results of a Multicenter Randomized Controlled Trial Comparing Heparin-Bonded Endoluminal to Femoropopliteal Bypass. JACC Cardiovasc Interv 2017; 10: 2320-2331
• 10 Bosiers M. ZilverPass-Presentation LINC 2019, Leipzig Januar 2019. Im Internet (Stand: 14.04.2020): https://www.leipzig-interventional-course.com/archive/linc-2019/presentations/
• 11 Bausback Y, Wittig T, Schmidt A. et al. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. J Am Coll Cardiol 2019; 73: 667-679
• 12 Gray WA, Keirse K, Soga Y. et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018; 392: 1541-1551
• 13 Torsello G, Stavroulakis K, Brodmann M. et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther 2019; in press
• 14 Katsanos K, Spiliopoulos S, Kitrou P. et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7: e011245
• 15 Freisinger E, Koeppe J, Gerss J. et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J 2019;
• 16 Bradbury AW, Adam DJ, Bell J. et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making. J Vasc Surg 2010; 51 (Suppl. 05) 52S-68S Erratum in: J Vasc Surg 2010; 52: 1751 Erratum in: J Vasc Surg 2010; 52: 1751
• 17 Rastan A, Brechtel K, Krankenberg H. et al. Sirolimus-eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents: Long-term Results from a Randomized trial. J Am Coll Cardiol 2012; 60: 587-591
• 18 Zeller T, Micari A, Scheinert D. et al. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial 5-Year Outcomes. JACC Cardiovasc Interv 2020; 13: 431-434
• 19 Mustapha J, Gray W, Martinsen BJ. et al. One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. J Endovasc Ther 2019; 26: 143-154
• 20 Zeller T, Cissarek T, Gray WA, Kröger K. Hrsg. Gefäßmedizin – Therapie und Praxis. 2. aktualisierte Auflage. Berlin: ABW-Wissenschaftsverlag; 2013